Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (REVB) is a clinical-stage biotechnology company pioneering immunologic therapeutics through its proprietary Gemini platform. This centralized news hub provides investors and healthcare professionals with essential updates on the company's inflammatory disease research and clinical developments.
Access timely reports on Revelation Biosciences' therapeutic pipeline including Gemini-SSI (surgical infection prevention), Gemini-AKI (acute kidney injury), and Gemini-CKD (chronic kidney disease) programs. Our curated news collection covers clinical trial milestones, regulatory updates, scientific presentations, and strategic partnerships relevant to TLR4 agonist development.
This resource serves investors tracking the company's progress in inflammation modulation and researchers monitoring PHAD-based therapeutic innovations. Content is rigorously verified to ensure accurate reporting on Revelation Biosciences' clinical-stage developments without speculative commentary.
Bookmark this page for streamlined access to REVB's latest press releases, peer-reviewed study findings, and material event disclosures. Check regularly for updates on the Gemini formulation's advancement through clinical testing phases and related biopharmaceutical industry developments.
Revelation Biosciences (NASDAQ: REVB) announced positive results from a study showing that Gemini effectively reduces inflammation in human peripheral blood mononuclear cells (PBMCs). The study demonstrated that Gemini-primed PBMCs, when exposed to inflammatory promoters HMGB-1 and LPS, showed significantly decreased proinflammatory cytokines and increased anti-inflammatory cytokines compared to placebo.
The company is currently conducting a Phase 1b PRIME clinical study in patients with Stage 3 and 4 Chronic Kidney Disease (CKD), with top-line data expected by mid 2025. This data will include safety, tolerability, and cellular-level protection assessment, supporting future development of GEM-CKD, GEM-AKI, and GEM-PSI programs.
Revelation Biosciences (NASDAQ: REVB), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, has announced its participation in the 37th Annual Roth Conference. James Rolke, the company's Chief Executive Officer, will engage in a fireside chat scheduled for Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.
The event will be accessible through a live webcast and will subsequently be available for viewing in the Investors section of Revelation's website at www.RevBiosciences.com. Interested investors can arrange meetings with the management team through their Roth representatives.
Revelation Biosciences (NASDAQ: REVB) has reported its financial results for Q4 and full-year 2024. The company ended the year with $6.5 million in cash, down from $12.0 million in 2023. Key developments include the initiation of the PRIME Phase 1b Clinical Study of Gemini in CKD Patients, FDA acceptance of Gemini IND, and securing $3.7 million from warrant exercises in December 2024.
Financial performance shows a net loss of $1.7 million ($4.98 per share) for Q4 2024, compared to $2.2 million loss in Q4 2023. The full-year 2024 resulted in a net loss of $15.0 million ($87.68 per share) versus $0.1 million loss in 2023. Cash used in operations increased to $18.3 million in 2024 from $7.3 million in 2023. Management believes current cash positions are sufficient to fund operations into 2025.
Revelation Biosciences (NASDAQ: REVB) has initiated patient dosing in its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of Gemini. The study focuses on evaluating intravenous single ascending doses in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).
The US-based, multi-site, placebo-controlled trial will include up to forty patients across five cohorts. The company expects to release top-line data by mid-year, which will assess safety, tolerability, and key biomarkers of activity, including attenuation of the inflammatory response. Results from this PRIME study will support future development of both GEM-CKD and GEM-AKI programs.
Revelation Biosciences (NASDAQ: REVB) has received formal notification from Nasdaq confirming its continued listing status, having met all compliance requirements. The company recently initiated its PRIME Phase 1b clinical study investigating intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).
The U.S. multi-site placebo-controlled study will evaluate escalating doses across five cohorts, enrolling up to 40 patients. CEO James Rolke emphasized that maintaining Nasdaq listing helps preserve stockholder liquidity, provides capital access, and aids in talent retention. The company plans to share study results with shareholders at each milestone throughout 2025.
Revelation Biosciences (NASDAQ: REVB) has announced a 1-for-16 reverse stock split effective January 28, 2025, following stockholder approval on January 17, 2025. The stock will continue trading under the symbol 'REVB' with a new CUSIP number 76135L606.
The reverse split aims to increase the market price per share to regain compliance with Nasdaq Capital Market's minimum bid listing requirements. Proportionate adjustments will be made to conversion and exercise prices of warrants, restricted stock units, stock options, and shares under equity incentive plans.
The company also announced the start of its Prime Phase 1b clinical study of Gemini in CKD patients, with dosing to begin in Mid-February 2025 and topline data expected Mid-Year.
Revelation Biosciences (NASDAQ: REVB) has initiated its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study for Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The study will evaluate escalating doses of intravenously administered Gemini across five cohorts, enrolling up to forty patients in a US-based multi-site placebo-controlled trial.
Dosing is scheduled to begin in mid-February, with topline data expected by mid-year. The results will include safety, tolerability, and biomarkers of target activity. The data from this PRIME clinical study will support future development in both the GEM-CKD and GEM-AKI programs.
Revelation Biosciences (NASDAQ: REVB) has announced a special meeting of stockholders scheduled for January 17, 2025. The key focus is on Proposal 2, which involves redomiciling the company from Delaware to Nevada, potentially saving the company over $200,000 annually in franchise tax fees.
The Board of Directors recommends shareholders vote in favor of all proposals. The meeting will be held virtually via Zoom videoconference, with telephone participation options available. Shareholders can vote by contacting Advantage Proxy at the provided toll-free numbers.
Revelation Biosciences (NASDAQ: REVB) has secured continued listing on the Nasdaq Stock Market following a decision by the Nasdaq Hearings Panel. The company must maintain its stock price at or above $1.00 for at least ten consecutive trading days by February 14, 2025. The Panel also confirmed REVB's compliance with the Equity Requirement of Listing Rule 5550(b)(1), addressing a previous delisting notice from August 14, 2024.
Recent developments include a successful $4 million warrant exercise on December 3, 2024, and FDA acceptance of the Gemini IND on December 2, 2024. The company plans to initiate a Phase 1b clinical study for chronic kidney patients in the first half of 2025, following the successful GMP manufacture of the Gemini drug product for clinical trials.
Revelation Biosciences (NASDAQ: REVB) announced a definitive agreement for the immediate exercise of outstanding warrants to purchase up to 4,064,040 shares of common stock at $1.00 per share, generating $4 million in gross proceeds. The exercising holders will receive new warrants in a private placement: Class F warrants for up to 4,064,040 shares and Class G warrants for up to 6,096,060 shares, both at $1.00 per share. Class F warrants have a 2-year term while Class G warrants have a 5-year term. Roth Capital Partners is acting as financial advisor for this transaction.
